Epigenetic Biomarkers of Lead Exposure and Cardiovascular Disease: Prospective Evidence in the Strong Heart Study
Wil Lieberman‐Cribbin,Arce Domingo‐Relloso,Ana Navas‐Acien,Shelley Cole,Karin Haack,Jason Umans,Maria Tellez‐Plaza,Elena Colicino,Andrea A. Baccarelli,Xu Gao,Allison Kupsco
DOI: https://doi.org/10.1161/JAHA.122.026934
2022-11-17
Abstract:Background Lead is a cardiotoxic metal with a variety of adverse health effects. In the absence of data on bone lead exposure, epigenetic biomarkers can serve as indicators of cumulative lead exposure and body burden. Herein, we leveraged novel epigenetic biomarkers of lead exposure to investigate their association with cardiovascular disease (CVD) incidence and mortality. Methods and Results Blood DNA methylation was measured using the Illumina MethylationEPIC BeadChip among 2231 participants of the Strong Heart Study (SHS) at baseline (1989–1991). Epigenetic biomarkers of lead levels in blood, patella, and tibia were estimated using previously identified cytosine‐guanine dinucleotide (CpG) sites. CVD incidence and mortality data were available through 2017. Median concentrations of lead epigenetic biomarkers were 13.8 μg/g, 21.3 μg/g, and 2.9 μg/dL in tibia, patella, and blood, respectively. In adjusted models, the hazard ratio (HR) (95% CI) of CVD mortality per doubling increase in lead epigenetic biomarkers were 1.42 (1.07–1.87) for tibia lead, 1.22 (0.93–1.60) for patella lead, and 1.57 (1.16–2.11) for blood lead. The corresponding HRs for incident CVD were 0.99 (0.83–1.19), 1.07 (0.89–1.29), and 1.06 (0.87–1.30). The association between the tibia lead epigenetic biomarker and CVD mortality was modified by sex (interaction P value: 0.014), with men at increased risk (HR, 1.42 [95% CI, 1.17–1.72]) compared with women (HR, 1.04 [95% CI, 0.89–1.22]). Conclusions Tibia and blood epigenetic biomarkers were associated with increased risk of CVD mortality, potentially reflecting the cardiovascular impact of cumulative and recent lead exposures. These findings support that epigenetic biomarkers of lead exposure may capture some of the disease risk associated with lead exposure. Nonstandard Abbreviations and Acronyms DNAm DNA methylation eBlood DNA methylation–based biomarker of lead exposure in blood ePatella DNA methylation–based biomarker of lead exposure in patella eTibia DNA methylation–based biomarker of lead exposure in tibia NAS Normative Aging Study SHS Strong Heart Study Clinical Perspective What Is New? Higher levels of epigenetic biomarkers of lead exposure estimated in tibia and blood were associated with increased risk of cardiovascular disease mortality. The association between the tibia lead epigenetic biomarker and cardiovascular disease mortality was modified by sex, with men at increased risk compared with women. What Are the Clinical Implications? In the absence of data on bone lead exposure, epigenetic biomarkers can serve as indicators of cumulative lead exposure. Epigenetic lead biomarkers can capture some of the cardiovascular risk associated with lead exposure. Lead (Pb) is a toxic metal associated with adverse cardiovascular, neurological, renal, hematological, immunological, reproductive, and developmental outcomes. 1 , 2 , 3 , 4 Before widespread bans in the 1970s, lead was included in gasoline, paint, water piping, and plumbing fixtures, resulting in extensive contamination of the air, soil, dust, and water. 5 Lead is still widely refined and processed in the United States, 6 where lead levels remain relatively high and individuals remain at risk of exposure. There is also evidence of racial and socioeconomic disparities concerning the burden of lead exposure, 7 , 8 , 9 with several racial and ethnic groups and low‐income populations facing increased exposures compared with other groups. Because of the persistence of lead in the environment and continuous new exposures, lead and its associated adverse health effects remain relevant today. Despite its importance as a potential cardiovascular risk factor, large cohort studies of cardiovascular disease (CVD) often lack data on lead exposure. Traditionally, biomarkers of lead exposure have been measured in blo -Abstract Truncated-